Simple parameters to solve a complex issue: predicting response to checkpoint inhibitor therapy in lung cancer.

James NewmanIsabel PreeshagulNina KohnCraig DevoeNagashree Seetharamu

Published in: Lung cancer management (2020)

Simple clinical biomarkers can predict response to ICIs. A score incorporating both clinical factors and established tissue/serum biomarkers may be useful in identifying NSCLC patients who would benefit from ICIs.

Keyphrases

small cell lung cancer
dna damage
stem cells
cell cycle
advanced non small cell lung cancer
mesenchymal stem cells
cell proliferation
bone marrow
brain metastases
replacement therapy